Print this page    •   Back to Web version of article

U.S. News
Study: Generics Could Cut Costs of HIV Treatment

January 15, 2013

HIV-infected patients may soon be able to switch from a branded one-pill combination of antiretroviral drugs to a less expensive protocol that combines generic and branded drugs. Current guidelines recommend HIV-infected people take the single-pill combination of efavirenz (Sustiva), emtricitabine (Emtriva), and tenofovir (Viread). The cheaper three-pill regimen would include a generic version of efavirenz, lamivudine (similar to emtricitabine), and Atripla. According to Rochelle Walensky, MD, the United States could see a savings of $920 million in the first year if every U.S. resident on antiretroviral therapy switched to the three-pill generic regimen.

However, Walensky noted that it is harder to adhere to the schedule of taking three pills, and lack of adherence can make treatment less effective. In addition, there is evidence that lamivudine is less effective than emtricitabine, and patients are more likely to develop resistance to lamivudine.

Massachusetts General Hospital researchers compared the cost and effectiveness of no treatment with the recommended single pill dose, a three-pill regimen, and an intermediate treatment consisting of two pills. The two-pill alternative would include a generic form of efavirenz and a branded combination of tenofovir and emtricitabine (Truvada). An HIV-infected person who receives no treatment from age 43 has a life expectancy of 4.05 quality-adjusted life-years (QALY). The branded single-pill treatment results in 12.45 QALY, compared with 12.25 QALY for the two-pill intermediate treatment, and 12.08 QALY for the three-pill generic treatment.

Lifetime cost for the person taking the branded one-pill dose is $342,800, whereas lifetime cost for the generic-based three-pill regimen is estimated to be $300,300.

The full report, "Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States," was published in the journal Annals of Internal Medicine (2013; 158(2):84-92).

[ Editor's Note, 1/18/2013: The original version of this article incorrectly stated that Atripla was the brand name of tenofovir, rather than Viread. We have corrected the error on this page.]

Back to other news for January 2013

Excerpted from:
MedPage Today
01.14.2013; Michael Smith

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.